SS
CERE

Steve Schonfeld’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Steve Schonfeld’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,400
Closed -$752K – 2553
2024
Q2 		$752K Sell
18,400
-100
-0.5% -$4.16K ﹤0.01% 1324
2024
Q1 		$782K Buy
18,500
+8,500
+85% +$357K 0.01% 1316
2023
Q4 		$424K Buy
+10,000
New +$287K ﹤0.01% 1339

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Steve Schonfeld's CERE Position: Q3 2024 in Review

Steve Schonfeld sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 42,575 shares — an estimated $1.74M sold.

Steve Schonfeld first reported a position in CERE in Q1 2021 and held it in 7 quarters. The position peaked at $2.11M in Q2 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Steve Schonfeld reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Steve Schonfeld sold 42,575 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.74M.
  • Steve Schonfeld first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • Steve Schonfeld's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $2.11M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.